Ravulizumab Shows Promise in Reducing Delayed Graft Function in Kidney Transplant Patients
A clinical trial is evaluating the efficacy of ravulizumab in reducing delayed graft function (DGF) in kidney transplant patients.
Asset / Drug
Drug and asset intelligence for ravulizumab with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Monoclonal Antibody
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.